Nucleic Acid Pathogen Testing - Cigna

← Back to document page

Medical Coverage Policy Effective Date ........................................ ..... 9/15/2021. Next Review 1/15/2022. Coverage Policy Number .................................. 0530. Nucleic acid Pathogen Testing Table of Contents Related Coverage Resources Overview ........................................ ...................... 1 Preventive Care Services Coverage General Background ........................................ ....3. Medicare Coverage Determinations ....................8. Coding/Billing Information ....................................9. References ........................................ ................36. INSTRUCTIONS FOR USE. The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients.

Nucleic acid tests are the most sensitive tests and are recommended by the CDC. These tests can be performed on easily obtainable specimens such as vaginal swabs (either clinician- or patient-collected) or urine. Chlamydia can be diagnosed by testing first-catch urine in both males and females or collecting swab specimens from the

  Pathogens, Testing, Acid, Recommended, Nucleic, Nucleic acid pathogen testing